Literature DB >> 11736870

Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers.

T Simon1, L Becquemont, B Hamon, E Nouyrigat, Y Chodjania, J M Poirier, C Funck-Brentano, P Jaillon.   

Abstract

AIMS: To assess the age-associated changes over time of plasma paraxanthine/caffeine (PAX/CAF) ratios used as a probe for CYP1A2 activity.
METHODS: Intraindividual and interindividual variabilities in PAX/CAF ratio were compared by phenotyping with caffeine, 16 young and 16 elderly healthy subjects on five occasions.
RESULTS: PAX/CAF ratio variability was comparable regardless of age (intraindividual CV: 17.6 +/- 6% and 16.2 +/- 5.9%, interindividual CV: 48.1 +/- 2.9% and 42.7 +/- 3.6% in young and elderly, respectively). The PAX/CAF ratio was lower in elderly than in young subjects (95% CI for the difference: 0.004, 0.32) but the difference was not significant in nonsmokers compared separately.
CONCLUSIONS: The variability over time of the PAX/CAF ratio is not influenced by age.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11736870      PMCID: PMC2014598          DOI: 10.1046/j.0306-5251.2001.01494.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained?

Authors:  O Spigset; S Hägg; E Söderström; R Dahlqvist
Journal:  Pharmacogenetics       Date:  1999-06

Review 2.  The use of caffeine for enzyme assays: a critical appraisal.

Authors:  W Kalow; B K Tang
Journal:  Clin Pharmacol Ther       Date:  1993-05       Impact factor: 6.875

3.  Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.

Authors:  U Fuhr; K L Rost
Journal:  Pharmacogenetics       Date:  1994-06

4.  Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment.

Authors:  A Rostami-Hodjegan; S Nurminen; P R Jackson; G T Tucker
Journal:  Pharmacogenetics       Date:  1996-04

5.  Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population.

Authors:  D S Ou-Yang; S L Huang; W Wang; H G Xie; Z H Xu; Y Shu; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

6.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

Authors:  T Shimada; H Yamazaki; M Mimura; Y Inui; F P Guengerich
Journal:  J Pharmacol Exp Ther       Date:  1994-07       Impact factor: 4.030

7.  Assessment of caffeine exposure: caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines.

Authors:  A Lelo; J O Miners; R Robson; D J Birkett
Journal:  Clin Pharmacol Ther       Date:  1986-01       Impact factor: 6.875

8.  Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements.

Authors:  B K Tang; Y Zhou; D Kadar; W Kalow
Journal:  Pharmacogenetics       Date:  1994-06

9.  Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.

Authors:  M A Butler; N P Lang; J F Young; N E Caporaso; P Vineis; R B Hayes; C H Teitel; J P Massengill; M F Lawsen; F F Kadlubar
Journal:  Pharmacogenetics       Date:  1992-06

10.  Interaction between two probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans.

Authors:  F Berthou; T Goasduff; D Lucas; Y Dréano; M H Le Bot; J F Ménez
Journal:  Pharmacogenetics       Date:  1995-04
View more
  9 in total

1.  A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.

Authors:  Céline Verstuyft; Xavier Delavenne; Alexandra Rousseau; Annie Robert; Michel Tod; Bertrand Diquet; Martine Lebot; Patrice Jaillon; Laurent Becquemont
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.

Authors:  Xia Yang; Bin Zhang; Cliona Molony; Eugene Chudin; Ke Hao; Jun Zhu; Andrea Gaedigk; Christine Suver; Hua Zhong; J Steven Leeder; F Peter Guengerich; Stephen C Strom; Erin Schuetz; Thomas H Rushmore; Roger G Ulrich; J Greg Slatter; Eric E Schadt; Andrew Kasarskis; Pek Yee Lum
Journal:  Genome Res       Date:  2010-06-10       Impact factor: 9.043

3.  Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes.

Authors:  Felix Stader; Marco Siccardi; Manuel Battegay; Hannah Kinvig; Melissa A Penny; Catia Marzolini
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

4.  Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly.

Authors:  Felix Stader; Hannah Kinvig; Melissa A Penny; Manuel Battegay; Marco Siccardi; Catia Marzolini
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447

5.  Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2015-07       Impact factor: 6.447

6.  Expression of cytochrome P450 isozyme transcripts and activities in human livers.

Authors:  Jie Liu; Yuan-Fu Lu; J Christopher Corton; Curtis D Klaassen
Journal:  Xenobiotica       Date:  2020-12-28       Impact factor: 1.908

Review 7.  Magnitude of Drug-Drug Interactions in Special Populations.

Authors:  Sara Bettonte; Mattia Berton; Catia Marzolini
Journal:  Pharmaceutics       Date:  2022-04-04       Impact factor: 6.525

8.  Effects of Common CYP1A2 Genotypes and Other Key Factors on Intraindividual Variation in the Caffeine Metabolic Ratio: An Exploratory Analysis.

Authors:  Dan-Dan Tian; Senthil Natesan; John R White; Mary F Paine
Journal:  Clin Transl Sci       Date:  2018-11-26       Impact factor: 4.689

9.  Evaluation of CYP1A2 activity: Relationship between the endogenous urinary 6-hydroxymelatonin to melatonin ratio and paraxanthine to caffeine ratio in dried blood spots.

Authors:  Gaëlle Magliocco; Jules Desmeules; Caroline Flora Samer; Aurélien Thomas; Youssef Daali
Journal:  Clin Transl Sci       Date:  2022-03-26       Impact factor: 4.438

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.